CAS
LAB icon

CTC Alternative Strategies’s Standard BioTools LAB Stock Holding History

CTC Alternative Strategies’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-57,600
Closed -$156K – 232
2024
Q1 		$156K Buy
+57,600
New +$139K 0.1% 58

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

CTC Alternative Strategies's LAB Position: Q2 2024 in Review

CTC Alternative Strategies sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 57,600 shares — an estimated $156K sold.

CTC Alternative Strategies first reported a position in LAB in Q1 2024 and held it in 1 quarter. The position peaked at $156K in Q1 2024. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

  • CTC Alternative Strategies reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 57,600 Standard BioTools shares in Q2 2024, an estimated $156K.
  • CTC Alternative Strategies first reported a position in Standard BioTools in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Standard BioTools position peaked at $156K in Q1 2024.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.